Issue Information

Issue Information
Publié: (2025)

Issue Information
Publié: (2025)

Issue Information
Publié: (2026)

Issue Information
Publié: (2024)

Issue Information
Publié: (2026)

Issue Information
Publié: (2024)

Issue Information
Publié: (2024)

Issue Information
Publié: (2026)

Issue Information
Publié: (2024)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
par: Juliette Penichoux, et autres
Publié: (2025)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
par: Tengfei Shi, et autres
Publié: (2025)

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
par: Akihiko Izumi, et autres
Publié: (2025)

444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
par: V. Musteata, et autres
Publié: (2025)

72 | SEQUOIA 5‐YEAR FOLLOW‐UP IN ARM C: FRONTLINE ZANUBRUTINIB IN PATIENTS WITH DEL(17P) AND TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
par: C. S. Tam, et autres
Publié: (2025)

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
par: Fuli Fan, et autres
Publié: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
par: Yutaka Shimazu, et autres
Publié: (2025)

598 | REDEFINING CLASSIFICATION ALGORITHM AND STAGING SYSTEM IN MARGINAL ZONE LYMPHOMA
par: C. Bommier, et autres
Publié: (2025)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
par: Dong Liang, et autres
Publié: (2025)

Autoimmune Complications of Lymphoproliferative Diseases
par: Wilma Barcellini, et autres
Publié: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Publié: (2025)

397 | ROBUST SINGLE AGENT ACTIVITY OF BI‐1808, A TUMOR NECROSIS FACTOR RECEPTOR 2 BLOCKER/DEPLETER, IN T CELL LYMPHOMA PATIENTS
par: S. Barta, et autres
Publié: (2025)

12 | IMAGING BIOMARKERS FOR THE DEFINITION OF RESPONSE IN THE GHSG HD18, GHSG HD21 AND LYSA AHL2011 TRIALS FOR ADVANCED‐STAGE HODGKIN LYMPHOMA
par: J. Ferdinandus, et autres
Publié: (2025)

15 | EARLY PET RESPONSE PREDICTS RISK OF RELAPSE AFTER 2L AXI‐CEL IN LARGE B‐CELL LYMPHOMA
par: A. Kuhnl, et autres
Publié: (2025)

301 | SOCIOECONOMIC DISPARITIES, DISEASE BURDEN AND TREATMENT INTENSITY IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA TREATED AT AN URBAN ACADEMIC CANCER CENTER
par: H. J. Cherng, et autres
Publié: (2025)

300 | DIFFUSE LARGE B‐CELL LYMPHOMA IN BRAZIL: A COMPREHENSIVE ANALYSIS OF SOCIODEMOGRAPHIC PATTERNS
par: G. Duffles, et autres
Publié: (2025)

75 | POPULATION‐WIDE INTRODUCTION OF DOSE‐ADJUSTED EPOCH‐R IN HIGH‐GRADE B‐CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS WITH DLBCL MORPHOLOGY
par: W. Alduaij, et autres
Publié: (2025)

578 | PATTERNS OF CHEMOIMMUNOTHERAPY USE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN THE US COMMUNITY SETTING
par: J. Burke, et autres
Publié: (2025)

767 | AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL FAILURE REQUIRING HEMODIALYSIS. A SINGLE‐CENTER EXPERIENCE
par: I. Kliuchagina, et autres
Publié: (2025)

610 | RELATIVE EFFICACY OF VENETOCLAX PLUS IBRUTINIB VERSUS BRUTON TYROSINE KINASE INHIBITOR MONOTHERAPY AND CHEMOIMMUNOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
par: N. Ghosh, et autres
Publié: (2025)

861 | BRIDGING RADIATION THERAPY IN CAR‐T THERAPY
par: T. Li, et autres
Publié: (2025)

827 | WITHDRAWN
Publié: (2025)

826 | PET‐CT–ADAPTED TREATMENT FOR EARLY‐STAGE DIFFUSE LARGE B‐CELL LYMPHOMA WITHOUT RISK FACTORS: PRELIMINARY ANALYSIS FROM THE GATLA GROUP
par: A. Cerutti, et autres
Publié: (2025)

553 | DIGITAL TECHNOLOGY AND NATURAL LANGUAGE PROCESSING IN ACTION: EXPLORING THE BELGIAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT POPULATION WITH THE BE‐CLLEAR STUDY
par: M. Vanderkerken, et autres
Publié: (2025)

837 | AXICABTAGENE CILOLEUCEL CAR T‐CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL B‐CELL LYMPHOMA
par: I. E. Karsten, et autres
Publié: (2025)

842 | MYHODGKIN MYHEALTH SURVIVORSHIP APP RECRUITMENT SUGGESTS HIGH ACCEPTABILITY OF PATIENT‐DERIVED DATA IN HODGKIN LYMPHOMA
par: N. Wong Doo, et autres
Publié: (2025)

196 | DNA METHYLATION SIGNATURES DISTINGUISH EXTRANODAL NK/T‐CELL LYMPHOMA AND EBV‐POSITIVE NODAL T/NK‐CELL LYMPHOMA AND IDENTIFY PROGNOSTIC SUBGROUPS
par: T. Phyu, et autres
Publié: (2025)